Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD) (NCT07115004)
A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients With Von Willebrand Disease (VIVID-6)
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
Who can join: Review the eligibility criteria below.
Location: Arkansas Children's Hospital — Little Rock, Arkansas
Age range: 12 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Arkansas Children's Hospital — Little Rock, Arkansas
- Luskin Orthopaedic Institute For Children — Los Angeles, California
- UC Davis Medical Center — Sacramento, California
- University of California San Francisco — San Francisco, California
- Emory University Hospital — Atlanta, Georgia
- Children's Healthcare of Atlanta — Atlanta, Georgia
- University of Minnesota — Minneapolis, Minnesota
- Science 37, Inc. (Virtual Clinical MetaSite) — Morrisville, North Carolina
- Hemophilia Center of Western PA — Pittsburgh, Pennsylvania
- UT Southwestern Children's Hospital — Dallas, Texas
- Washington Center for Bleeding Disorders — Seattle, Washington
- K Eristavi National Center of Experimental and Clinical Surgery (ქირურგიის ეროვნული ცენტრი) — Tbilisi,
- Frankfurt University Hospital (Universitätsmedizin Frankfurt) — Frankfurt,
- Charlotte Maxeke Johannesburg Academic Hospital School of Pathology Clinical Haematologist — Johannesburg,
📞 Contact the Study Coordinator
Phone: (650) 466-8041
Email: medinfo@star-therapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Von Willebrand Disease (VWD)
- A Study of Bleeding and Treatment in Participants With Von Willebrand Disease — Phoenix, Arizona
- A Study Assessing HMB-002 in Participants With Von Willebrand Disease — Phoenix, Arizona
- A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD) — Birmingham, Alabama
- HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB — Los Angeles, California
Explore by condition: All Von Willebrand Disease (VWD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.